Tn-MUC1 DC vaccination of rhesus macaques and a Phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer

Cancer Immunology Research

Volumn 4, Issue 10, 2016, Pages 881-892

  Scheid, Elizabeth ^a,i,j   Major, Pierre ^a,b   Bergeron, Alain ^c,d   Finn, Olivera J ^e   Salter, Russell D ^e,k   Eady, Robin ^b   Yassine Diab, Bader ^f   Favre, David ^f,l   Peretz, Yoav ^f   Landry, Claire ^f   Hotte, Sebastien ^b   Mukherjee, Som D ^b   Dekaban, Gregory A ^g   Fink, Corby ^g   Foster, Paula J ^g   Gaudet, Jeffery ^g   Gariepy, Jean ^h   Sekaly, Rafick Pierre ^i,m   Lacombe, Louis ^c,d   Fradet, Yves ^c,d   Foley, Ronan ^a,b   more..

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c Université Laval   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

^h Institute of Clinical Evaluative Sciences   (Canada)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k University of Louisville School of Medicine   (United States)

^l GLAXOSMITHKLINE   (United States)

^m CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CANCER VACCINE; GLUCOPYRANOSYL LIPID ADJUVANT; PROSTATE SPECIFIC ANTIGEN; TN GLYCOSYLATED MUCIN 1 GLYCOPEPTIDE DENDRITIC CELL VACCINE; UNCLASSIFIED DRUG; MUC1 PROTEIN, HUMAN; MUCIN 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANDIDIASIS; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL TRACKING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DENDRITIC CELL; DRUG SAFETY; FATIGUE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFECTION; INSOMNIA; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRECLINICAL STUDY; PROTEIN EXPRESSION; RHESUS MONKEY; VERY ELDERLY; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; FEASIBILITY STUDY; IMMUNOLOGY; TRANSPLANTATION; VACCINATION;

AGED; AGED, 80 AND OVER; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEASIBILITY STUDIES; HUMANS; MACACA MULATTA; MALE; MIDDLE AGED; MUCIN-1; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VACCINATION;

EID: 84994165280     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0189     Document Type: Article

References (52)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der KT, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37.
3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der KT, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-79.
4. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013; 190: 429-38.
5. Berthold DR, Pond GR, Soban F, de WR, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
6. Singh BH, Gulley JL. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014; 2: 137-48.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
8. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014; 33: 641-55.
9. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-12.
10. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014; 63: 407-18.
11. Burotto M, Singh N, Heery CR, Gulley JL, Madan RA. Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol 2014; 4: 351.
12. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8: 551-61.
13. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005; 105: 2132-4.
14. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
15. Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 2013; 13: 35-49.
16. Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2010; 2: 305-27.
17. Major P, Lavallee M, Minassian H, Kovac P, Wang NS. Ultrastructural localization of a breast tumor-associated antigen. J Histochem Cytochem 1987; 35: 375-9.
18. Hanisch FG, Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000; 10: 439-49.
19. Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Tumor-associated glycans and immune surveillance. Vaccines 2013; 1: 174-203.
20. Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, et al. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One 2012; 7: e50139.
21. Von Mensdorff-Pouilly S, Moreno M, Verheijen RH. Natural and induced humoral responses to MUC1. Cancers (Basel) 2011; 3: 3073-103.
22. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 1998; 161: 5500-6.
23. + T cells. Cancer Res 1998; 58: 5066-70.
24. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999; 194: 143-9.
25. Chen D, Koido S, Li Y, Gendler S, Gong J. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat 2000; 60: 107-15.
26. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 2783-92.
27. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013; 6: 18-26.
28. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002; 196: 1435-46.
29. Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009; 390: 611-8.
30. Ryan SO, Turner MS, Gariepy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res 2010; 70: 5788-96.
31. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50: 261-8.
32. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011; 6: e16333.
33. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005; 298: 61-72.
34. Helfer BM, Balducci A, Nelson AD, Janjic JM, Gil RR, Kalinski P, et al. Functional assessment of human dendritic cells labeled for in vivo (19) F magnetic resonance imaging cell tracking. Cytotherapy 2010; 12: 238-50.
35. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 671-7.
36. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-7.
37. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15: 2531-40.
38. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol 2006; 36: 2544-55.
39. Dekaban GA, Hamilton AM, Fink CA, Au B, de Chickera SN, Ribot EJ, et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013; 5: 469-83.
40. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150-6.
41. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107: 67-74.
42. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829-33.
43. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006; 66: 811-21.
44. Jahnisch H, Fussel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010; 2010: 517493.
45. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013; 81: 1297-302.
46. Strasser EF, Eckstein R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus Med Rev 2010; 24: 130-9.
47. Hong JH, Kim IY. Nonmetastatic castration-resistant prostate cancer. Korean J Urol 2014; 55: 153-60.
48. Westdorp H, Skold AE, Snijer BA, Franik S, Mulder SF, Major PP, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014; 5: 191.
49. + T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
50. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2014; 2: 91-8.
51. +T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18: 5460-70.
52. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173: 5372-80.